Dr Jackie Kinyamu-Akunda is a toxicologist and translational safety leader with over 20 years of experience advancing innovative therapeutics from discovery through registration. She is Vice President and Head of Nonclinical Safety at Incyte, where she leads nonclinical safety strategy across a diverse portfolio of small molecules, biologics, and emerging modalities in multiple disease areas.

Prior to joining Incyte, Jackie held roles of increasing responsibility at Johnson & Johnson Innovative Medicines, Novartis Institutes for BioMedical Research, and Eli Lilly and Company.